<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested dose adjustments of low molecular weight (LMW) heparins in adults with renal insufficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested dose adjustments of low molecular weight (LMW) heparins in adults with renal insufficiency</h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested dose adjustments of low molecular weight (LMW) heparins in adults with renal insufficiency</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">VTE treatment</td> <td class="subtitle1">VTE prophylaxis*</td> </tr> <tr> <td><strong>Enoxaparin</strong></td> <td> <p><strong>CrCl ≥30 mL/min:</strong> No adjustment</p> <strong>CrCl &lt;30 mL/min:</strong> Reduce to 1 mg/kg once daily</td> <td> <p><strong>CrCl ≥30 mL/min:</strong> No adjustment</p> <strong>CrCl &lt;30 mL/min:</strong> Reduce to 30 mg once daily (medical or surgical patients)</td> </tr> <tr> <td><strong>Dalteparin</strong></td> <td> <p><strong>CrCl ≥30 mL/min:</strong> No adjustment</p> <strong>CrCl &lt;30 mL/min:</strong> Use an anticoagulant with less dependence on renal clearance<sup>¶</sup></td> <td><strong>CrCl ≥30 mL/min:</strong> No adjustment</td> </tr> <tr> <td> <p><strong>Nadroparin</strong></p> (not available in the US)</td> <td> <p><strong>CrCl ≥50 mL/min:</strong> No adjustment</p> <p><strong>CrCl 30 to 50 mL/min:</strong> Reduce dose by 25 to 33% if clinically warranted</p> <strong>CrCl &lt;30 mL/min:</strong> Contraindicated</td> <td> <p><strong>CrCl ≥50 mL/min:</strong> No adjustment</p> <p><strong>CrCl 30 to 50 mL/min:</strong> Reduce dose by 25 to 33% if clinically warranted</p> <strong>CrCl &lt;30 mL/min:</strong> Reduce dose by 25 to 33%</td> </tr> <tr> <td> <p><strong>Tinzaparin</strong></p> (not available in the US)</td> <td> <p><strong>CrCl ≥30 mL/min:</strong> No adjustment</p> <strong>CrCl &lt;30 mL/min:</strong> Use with caution, although evidence suggests no accumulation with CrCl as low as 20 mL/min</td> <td> <p><strong>CrCl ≥30 mL/min:</strong> No adjustment</p> <strong>CrCl &lt;30 mL/min:</strong> Use with caution, although evidence suggests no accumulation with CrCl as low as 20 mL/min</td> </tr> </tbody></table></div><div class="graphic_lgnd">Suggested dose adjustment of LMW heparins for reduced renal function (subcutaneous dosing). Caution should be used in all patients with renal insufficiency, and all patients should be observed for signs of bleeding. Accumulation may occur with repeated doses. An alternative anticoagulant such as unfractionated heparin may be preferred, especially for individuals with CrCl &lt;30 mL/min, with renal failure, or receiving dialysis. Examples of alternatives include:<sup>[1]</sup>
<ul class="decimal_heading">
<li>Unfractionated heparin</li>
<li>An LMW heparin with lower renal clearance</li>
<li>A DOAC with low renal clearance (apixaban, renal clearance approximately 25%)</li>
</ul>
<p class="extra_spacing_top">Use of LMW heparin in patients with renal insufficiency has been associated with hyperkalemia. Refer to the UpToDate topics on the use of heparin and LMW heparin in specific clinical conditions, for infants and children, and for acute coronary syndromes and myocardial infarction (for which there are separate tables).</p></div><div class="graphic_footnotes"><p>VTE: venous thromboembolism; CrCl: creatinine clearance as determined by Cockcroft-Gault equation (a calculator is available in UpToDate); US: United States; LMW heparin: low molecular weight heparin; DOAC: direct oral anticoagulant.</p>
<p>* Applies to short-term VTE prophylaxis (up to 10 days). For long-term use, periodic anti-factor Xa activity testing may be useful to rule out drug accumulation.</p>
<p>¶ May consider checking anti-factor Xa activity, consistent with some authorities;<sup>[2-4]</sup> however, ranges have not been established from clinical trials and no dose adjustment nomograms have been clinically validated. Other experts and a 2018 guideline from the American Society of Hematology recommend against checking anti-factor Xa activity and suggest dose adjustments based on information in the product labeling or switching to an alternative anticoagulant such as those listed above. If monitored, levels should be measured 4 to 6 hours after dosing, following at least the third or fourth dose.<sup>Δ</sup></p>
Δ The following represent peak (4 hours after the dose) expected on-therapy values for therapeutic dosing (for VTE) for anti-factor Xa activity, although these have not been clinically validated:<sup>[1,2]</sup>
<ul>
<li>Enoxaparin twice daily: 0.6 to 1.0 anti-factor Xa units/mL (range, 0.5 to 1.5<sup>[5]</sup>)</li>
<li>Enoxaparin once daily: &gt;1.0 anti-factor Xa units/mL</li>
<li>Dalteparin once daily: 1.05 anti-factor Xa units/mL (range, 0.5 to 1.5<sup>[6]</sup>)</li>
<li>Nadroparin once daily: 1.3 anti-factor Xa units/mL<sup>[7]</sup></li>
<li>Tinzaparin once daily: 0.85 anti-factor Xa units/mL<sup>[8]</sup></li>
</ul></div><div class="graphic_reference">Data from:
<ol>
<li>Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Advances 2018; 3257.</li>
<li>Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.</li>
<li>Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: Available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064.</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc.</li>
<li>Enoxaparin sodium injection. US FDA approved prescribing information (revised October, 2013). Available at: <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020164s102lbl.pdf" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020164s102lbl.pdf</a>.</li>
<li>Dalteparin sodium injection. US FDA approved prescribing information (revised May, 2019). Available at: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020287s072lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020287s072lbl.pdf</a>.</li>
<li>Nadroparin calcium injection. Canada product monograph (revised January 2019). Available at: <a href="https://pdf.hres.ca/dpd_pm/00049107.PDF" target="_blank">https://pdf.hres.ca/dpd_pm/00049107.PDF</a>.</li>
<li>Tinzaparin sodium injection. Canada product monograph (May 26, 2017). Available at: <a href="https://pdf.hres.ca/dpd_pm/00040736.PDF" target="_blank">https://pdf.hres.ca/dpd_pm/00040736.PDF</a>.</li>
</ol></div><div id="graphicVersion">Graphic 90258 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
